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Abstract
Concerns about the pharmaceutical industry’s influence in academic medical centers and on medical
education have led many medical schools and teaching hospitals to adopt conflict-of-interest (COI) policies.
Although the restrictiveness of these policies differs, the goal is the same: to shield physicians-in-training from
the persuasive aspects of pharmaceutical promotion. But do these policies work? This Issue Brief examines
how COI policies affect the prescribing patterns of antidepressants, one of the most heavily promoted drug
classes in the past decade. As such, it provides the first empirical evidence of the effects of COI policies in
residency on the subsequent prescribing patterns of practicing physicians.
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Editor’s note: Concerns about the pharmaceutical industry’s influence in 
academic medical centers and on medical education have led many medical 
schools and teaching hospitals to adopt conflict-of-interest (COI) policies. 
Although the restrictiveness of these policies differs, the goal is the same: to shield 
physicians-in-training from the persuasive aspects of pharmaceutical promotion. 
But do these policies work? This Issue Brief examines how COI policies affect the 
prescribing patterns of antidepressants, one of the most heavily promoted drug 
classes in the past decade. As such, it provides the first empirical evidence of the 
effects of COI policies in residency on the subsequent prescribing patterns of 
practicing physicians. 
Physicians interact with the pharmaceutical industry throughout their professional 
lives—from medical school through residency training, and commonly in clinical 
practice. There is particular concern about industry influence on physician 
trainees, who are beginning to establish long-term practice patterns. In the past 
10 years, a number of guidelines have emerged to structure these interactions. 
•	 In	2002,	the	Pharmaceutical	Research	and	Manufacturers	Association	(PhRMA)	
issued voluntary guidelines for sales representatives that limited the value of 
gifts to physicians to under $100, along with other restrictions. At the same 
time,	the	American	Medical	Student	Association	(AMSA)	began	a	PharmFree	
Campaign to limit the access and influence of pharmaceutical companies at 
medical schools and academic medical centers. 
•	 In	2008,	the	Association	of	American	Medical	Colleges	(AAMC)	developed	
consensus principles for COI policies, including a prohibition on all gifts to 
health	care	professionals.	The	AAMC	guidelines	addressed	other	interactions	as	
well, including meals, pharmaceutical samples, and site access by 
sales representatives.
•	 Since	2007,	AMSA	has	issued	an	annual	“PharmFree	Scorecard”	grading	each	
medical school’s COI policy for its content and stringency. This scorecard shows 
that academic medical centers vary widely in their adoption of COI policies, 
even	after	the	AAMC	guidelines	were	issued.	In	2011-12,	18%	of	US	medical	
schools	received	an	“A,”	49%	a	“B,”	10%	a	“C,”	9%	a	“D”,	and	6%	an	“F.”
Policies target 
interactions between 
physician trainees and 
pharmaceutical companies
Although many studies indicate that contact with the pharmaceutical industry 
can affect physicians’ attitudes and prescribing choices, it is unknown whether 
exposure to COI policies during residency training attenuates that influence after 
graduation. Epstein and colleagues chose to study one specialty—psychiatry—
and one class of drug—antidepressants—to begin to answer that question. 
Antidepressants have been among the most heavily promoted drug classes, and 
antidepressant	use	increased	nearly	400%	from	1988	to	2008.	
•	 The	investigators	used	national	prescribing	data	for	2009	and	compared	two	
cohorts	of	psychiatrists:	those	completing	residency	in	2001	(before	COI	policy	
adoption)	and	those	completing	residency	in	2008	(after	COI	policy	adoption).	
•	 They	used	data	from	the	2008	AMSA	PharmFree	Scorecard	and	the	Institute	
for	Medicine	as	a	Profession	(IMAP)	to	sort	the	2008	COI	policies	of	
residency programs into three levels of restrictiveness (maximally, moderately, 
or minimally restrictive). The categorization was based on 10 aspects of each 
program’s policy: gifts, on-site meals, detailing, samples, purchasing and 
formularies, continuing medical education, consulting, speaking, travel, and 
industry support for trainees.
•	 They	analyzed	the	proportions	of	new	prescriptions	written	by	each	psychiatrist	
for	antidepressants	that	were:	(1)	heavily	promoted;	(2)	brand	reformulated 
(for example, controlled released versions); and (3) brand drugs. They 
categorized Lexapro and Cymbalta as heavily promoted, because these 
antidepressants were ranked first and third among all pharmaceuticals by 
promotional	spending	in	2009.
•	 To	estimate	the	effects	of	exposure	to	COI	policies,	the	investigators	compared	
the	average	difference	in	prescribing	during	2009	between	psychiatrists	
who	graduated	in	2001	and	in	2008	from	residency	programs	that	adopted	
maximally, moderately and minimally restrictive COI policies. If COI policies 
“work”	as	intended,	the	prescription	patterns	of	2008	graduates	of	the	most	
restrictive	programs	should	vary	the	most	from	their	2001	predecessors,	
compared to the least restrictive programs.
New study looks at how 
conflict of interest (COI) 
policies are associated 
with subsequent 
prescribing patterns
The	study	included	1,652	psychiatrists,	about	half	of	whom	graduated	in	2001	
and	half	in	2008.	They	accounted	for	901,805	new	dispensed	prescriptions	for	
antidepressants	in	2009.	
•	 The	psychiatrists	graduated	from	162	residency	programs.	Categorized	by	
their	program’s	2008	COI	policy,	about	30%	graduated	from	the	minimally	
restrictive	group,	51%	from	the	moderately	restrictive	group,	and	19%	from	the	
maximally restrictive group. 
•	 Overall,	the	2008	graduates	prescribed	far	fewer	antidepressants	than	the	
2001	graduates,	likely	because	they	were	in	their	first	year	of	practice	and	
consequently saw fewer patients.
•	 Not	surprisingly,	the	rates	of	prescribing	new	dispensed	antidepressants	among	
2001	graduates	were	not	significantly	different	across	residency	program	groups,	
since the COI policies were not in place at that time. 
Study analyzes more than 
900,000 new prescriptions 
for antidepressants by 
psychiatrists
Continued on back.
POLICY IMPLICATIONS Longstanding concerns have been raised about pharmaceutical industry influence 
on physicians in general and trainees in particular. This study provides the first 
empirical evidence about whether COI policies reduce this influence.
•	 In	psychiatry,	physicians	who	were	exposed	to	maximally	restrictive	COI	
policies during residency training had lower rates of prescribing heavily 
marketed antidepressants. Although physician-industry interactions may serve 
an important informational function, these results offer one piece of evidence 
that these COI policies have helped inoculate physicians against the persuasive 
aspects of pharmaceutical promotion. 
Rates	of	prescribing	heavily	promoted,	brand	reformulated,	and	brand	
antidepressants	in	2009	were	lower	among	post-COI	graduates	at	all	levels	of	COI	
restrictiveness. But the largest differences between pre- and post-COI graduates 
appeared in the maximally restrictive programs. 
•	 As	shown	below,	relative	to	the	2001	graduates	in	the	same	residency	group,	
2008	graduates	in	maximally	restrictive	programs	prescribed	heavily	marketed	
antidepressants	significantly	less	often	than	2008	graduates	of	both	minimally	
restrictive	programs	(4.3	percentage	points)	and	moderately	restrictive	programs	
(3.6	percentage	points).	
Exposure to restrictive COI 
policies in residency is 
associated with changes in 
prescribing patterns 
in practice
•	 Results	were	consistent	for	prescribing	of	brand	reformulations	and	brand	
drugs.	Relative	to	the	2001	graduates	in	the	same	residency	group	(who	
completed their training before their program adopted COI policies), 
prescribing	rates	among	2008	graduates	in	maximally	restrictive	programs	
were	significantly	lower	than	among	2008	graduates	of	minimally	restrictive	
programs for both reformulations (3.0 percentage points) and brand 
antidepressants	(4.5	percentage	points).
•	 Results	were	similar	when	the	analysis	included	both	new	and	refilled	
prescriptions for antidepressants.
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POLICY IMPLICATIONS
Continued
•	 Because	heavily	marketed	drugs,	reformulated	drugs,	and	brand	drugs	tend	
to be more expensive, a shift away from them could help reduce cost growth. 
However, it will be important to assess how lower costs achieved through 
stringent COI policies affect treatment effectiveness and quality of care. 
•	 Further	research	should	assess	whether	these	policies	have	affected	other	drug	
classes and physician specialties similarly.
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